{"id":"NCT02984644","sponsor":"The University of Texas Health Science Center at San Antonio","briefTitle":"Paradoxical Stimulation of Hepatic Glucose Production With Dapagliflozin","officialTitle":"Paradoxical Stimulation of Hepatic Glucose Production With Dapagliflozin (P2)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2017-09-06","primaryCompletion":"2018-11-16","completion":"2019-11-16","firstPosted":"2016-12-07","resultsPosted":"2019-12-18","lastUpdate":"2019-12-18"},"enrollment":30,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"SINGLE","primaryPurpose":"TREATMENT"},"conditions":["Type II; Diabetes"],"interventions":[{"type":"DRUG","name":"Dapagliflozin","otherNames":["Farxiga"]},{"type":"DRUG","name":"Placebo","otherNames":["Placebo for Dapagliflozin"]}],"arms":[{"label":"Dapagliflozin","type":"ACTIVE_COMPARATOR"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"To determine the role of plasma glucagon and insulin in the rise of endogenous glucose production (EGP) following the SGLT2 inhibition.","primaryOutcome":{"measure":"Measurement of the Change in Plasma Glucose (mg/dL): Study 1","timeFrame":"Baseline to 240-300 minutes","effectByArm":[{"arm":"Dapagliflozin 10mg","deltaMin":-29,"sd":4},{"arm":"Placebo","deltaMin":-17,"sd":3}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":2},"locations":{"siteCount":1,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":20},"commonTop":[]}}